Sunday 18 October 2026
Export FEED’s income statement to Excel — free account
ENvue Medical, Inc.
FEED Healthcare Medical Devices
ENvue Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue fell 51.6%, EPS grew 75.8%, free cash flow grew 19.8% and total debt fell 45.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.37
0.12
−24.49%
Follow FEED
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.65 | 3.59 | 0.57 | 1.80 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.18) | (1.81) | (0.54) | (2.46) | |
P/B ratio |
0.10 | 0.24 | 0.04 | 0.11 | |
Price to Tangible BV |
0.00 | 0.00 | 41.42 | 0.00 | |
EV/Sales |
1.63 | 3.06 | (0.66) | (0.40) | |
EV/EBITDA |
0.00 | 0.00 | 0.16 | 0.12 | |
EV/Operating CF |
(0.27) | (0.54) | 0.18 | 0.15 | |
EV/FCF |
(0.27) | (0.54) | 0.18 | 0.15 | |
Quick Ratio |
0.18 | 0.38 | 0.68 | 0.62 | |
Current Ratio |
0.66 | 0.90 | 1.09 | 0.86 | |
Net Debt/EBITDA |
0.01 | 0.34 | 0.93 | 2.98 | |
Debt/Assets |
2.81% | 2.71% | 2.63% | 1.92% | |
Debt/Equity |
0.04 | 0.03 | 0.03 | 0.02 | |
Asset Turnover |
0.04 | 0.05 | 0.11 | 0.09 | |
Operating CF/Net income |
0.22 | 0.19 | 0.20 | 2.53 | |
Capex/Depreciation |
(0.12) | (0.08) | 0.00 | (0.11) | |
Interest Coverage |
9.55 | (47.58) | 9.60 | 0.80 | |
Research and Development Expense of Revenue |
213.39% | 71.67% | (1.60%) | 30.61% | |
Selling, General and Administrative Expense of Revenue |
1,965.69% | 488.21% | 1,056.09% | 306.79% | |
Intangible Assets out of Total Assets |
0.86 | 0.83 | 0.81 | 0.81 | |
Share Based Compensation of Revenue |
856.90% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.89) | (0.21) | (0.25) | (0.39) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(275.74%) | (320.60%) | (1,319.20%) | (2,148.77%) | |
Free Cash Flow Yield |
(370.51%) | (158.62%) | (650.59%) | (150.46%) | |
Revenue per Share |
0.47 | 2.38 | 5.97 | 10.10 | |
Operating CF per Share |
(5.25) | (15.74) | (51.17) | (27.55) | |
Capex per Share |
(0.05) | (0.06) | (0.44) | (0.39) | |
Free Cash Flow per Share |
(5.30) | (15.80) | (51.61) | (27.94) | |
Cash per Share |
2.22 | 8.27 | 81.34 | 97.62 | |
Shareholders Equity per Share |
59.97 | 116.84 | 640.48 | 593.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
59.97 | 116.84 | 640.48 | 593.90 | |
Free Cash Flow |
(2.72) | (4.33) | (2.70) | (2.00) | |
Working Capital |
(2.49) | (0.67) | 0.61 | (1.63) | |
Capital Expenditures |
(0.03) | (0.02) | (0.02) | (0.03) | |
Net Current Asset Value |
(2.83) | (1.66) | (0.36) | (1.90) | |
EV/EBIT |
0.00 | 0.00 | 0.07 | 0.11 | |
Capex to Sales |
0.11 | 0.03 | 0.07 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.16 | 0.35 | 0.19 | 0.42 | |
Average Payables |
4.12 | 3.85 | 1.80 | 3.60 | |
Average Inventory |
2.39 | 2.14 | 2.26 | 2.25 | |
Average Assets |
44.94 | 41.99 | 22.38 | 29.53 | |
Average Common Equity |
35.62 | 33.85 | 17.06 | 22.17 |
Columns are period end dates